LGM Pharma, a provider of tailored API and CDMO services for the full drug product lifecycle, is investing over $6 million to expand its Rosenberg, Texas manufacturing facility as part of its Phase I CDMO growth strategy. The expansion will increase capacity for liquid, suspension, semi-solid, and suppository drug products, addressing the rising demand for reliable U.S.-based production. The Rosenberg facility enhancements will accommodate increased production volumes while ensuring complianc...